Shinozaki Tetsuya, Saito Kenichi, Kobayashi Tsutomu, Yanagawa Takashi, Takagishi Kenji
Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Japan.
Open Orthop J. 2012;6:392-9. doi: 10.2174/1874325001206010392. Epub 2012 Sep 3.
Serum tartrate-resistant acid phosphatase (TRACP) 5b was investigated for use as a marker for diagnosis of giant cell tumor (GCT) of bone and for detection of its recurrence.Four patients with GCT of bone who were initially referred to our hospital were classified as a primary group. Three patients who had local recurrence following curettage were classified as a local recurrence group. Five with no recurrence were classified as a no-recurrence group. Eighteen patients with primary and metastatic malignant bone tumors were also enrolled in the study as a control group. Serum TRACP 5b was measured before the biopsy in all patients and was measured periodically after the operation in patients with GCT of bone. Student t-tests were used for statistical analyses.TRACP 5b was greater than 1500 Um/dL in all primary group patients. Mean TRACP 5b values decreased gradually with post-operative time, showing lower values until local recurrence. The mean value of TRACP 5b of the local recurrence group (753 ± 68.7 mU/dL) was significantly higher than that of the no-recurrence group (340.6 ± 78.3 mU/dL). The mean value of TRACP 5b of the control group (466.9 ± 130.3 mU/dL) was much lower than that of the primary group and markedly lower than that of the local recurrence group. However, no significant difference was found between the no-recurrence group and the control group.Serum TRACP 5b is a useful and convenient marker for diagnosing GCT of bone and for predicting its recurrence.
研究了血清抗酒石酸酸性磷酸酶（TRACP）5b作为骨巨细胞瘤（GCT）诊断标志物及其复发检测的应用。最初转诊至我院的4例骨巨细胞瘤患者被分类为原发组。3例刮除术后局部复发的患者被分类为局部复发组。5例无复发的患者被分类为无复发组。18例原发性和转移性恶性骨肿瘤患者也作为对照组纳入研究。所有患者在活检前测定血清TRACP 5b，骨巨细胞瘤患者术后定期测定。采用学生t检验进行统计分析。所有原发组患者的TRACP 5b均大于1500 U/L。TRACP 5b的平均值随术后时间逐渐降低，在局部复发前显示较低值。局部复发组的TRACP 5b平均值（753±68.7 mU/L）显著高于无复发组（340.6±78.3 mU/L）。对照组的TRACP 5b平均值（466.9±130.3 mU/L）远低于原发组，且明显低于局部复发组。然而，无复发组与对照组之间未发现显著差异。血清TRACP 5b是诊断骨巨细胞瘤及其预测复发的一种有用且便捷的标志物。
